Search Results 211-220 of 7944 for TNF
Inclusion Criteria: All adults age ≥ 18 years old. Exposure or non exposure to an antibiotic. Hypersensitivity reaction to vancomycin. Exclusion Criteria:.
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated ...
... TNF-α antagonist or vedolizumab or ustekinumab, or having documented intolerance (occurrence, at any time, of an unacceptable level of treatment-related ...
... TNF-α agents) within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during study treatment ...
About this study. A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to ...
About this study. The purpose of this study is to determine whether changes in the following parameters of cardiac function with low intensity exercise ...
Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a ...
... TNF agents in patients with IBD · Article. Research establishes strong association between family history and increased risk of colorectal cancer in patients ...
... tumor necrosis factor-alpha in human epithelial tumor cells. J Cell Biochem. 1992 Feb; 48 (2):203-14. View PubMed; Marusic M, Bajzer Z, Freyer JP, Vuk ...
... TNF treatment, abatacept, alemtuzumab, IVIg, belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening; For patients scheduled to receive ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your GivingTuesday gift can go 2X as far.